Alnylam Pharmaceuticals, Inc.

Wyeth

Axcella Health Inc.

Eleven Biotherapeutics, Inc.

Sesen Bio, Inc.

David V Erbe

Kevin Fitzgerald

Gregory Hinkle

Brian R Bettencourt

Eric Steven Furfine

William Querbes

Jinbo Lee

Zhao-Kui Wan

Steve Yikkai Tam

Michael J Smith

Thomas M Barnes

Kenneth W Foreman

Abigail Liebow

Alison Tisdale

Michael March Schmidt

Weixin Xu

David Arthur Berry

Douglas Wilson

Bruce Follows

Michael Hamill

Yan-Ling Zhang

Nathaniel Silver

Chung-Wei Lee

Diane Marie Joseph-McCarthy

Ying-Ja Chen

Eva Deanna Binnun

Steven J Kirincich

Alison Williams

Luke Hamm

Alessandro Fabio Moretto

Tracy L McGregor

Jun-Jun Wu

The invention relates to double stranded ribonucleic acid (dsRNA) compositions targeting a glucokinase (GCK) gene, as well as methods of inhibiting expression of a glucokinase (GCK) gene, and methods of treating subjects having a glycogen storage disease (GSD), e.g., type Ia GSD.

Glucokinase (GCK) iRNA compositions and methods of use thereof

Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

IL-6 antagonists and uses thereof

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.

Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof

This invention relates to modulating (e.g., inhibiting) protein tyrosine phosphatase 1B (PTP1B).

PTP1b inhibitors

Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.

Inhibitors of protein tyrosine phosphatase 1B

Growing community of inventors

Arlington, MA, United States of America

David V Erbe